High expression of SLC38A1 predicts poor prognosis in patients with de novo acute myeloid leukemia

2019 ◽  
Vol 234 (11) ◽  
pp. 20322-20328 ◽  
Author(s):  
Yan Li ◽  
Haigang Shao ◽  
Zhenzhen Da ◽  
Jinlan Pan ◽  
Bin Fu
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Poor Prognosis ◽  
De Novo ◽  
High Expression ◽  
Acute Myeloid

scholarly journals High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia

1998 ◽  
Vol 9 (2) ◽  
pp. 159-165 ◽  
Author(s):  
T. Karakas ◽  
U. Maurer ◽  
E. Weidmann ◽  
C.C. Miething ◽  
D. Hoelzer ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Poor Prognosis ◽  
High Expression ◽  
Acute Myeloid

High expression of miR‐338 is associated with poor prognosis in acute myeloid leukemia undergoing chemotherapy

2019 ◽  
Vol 234 (11) ◽  
pp. 20704-20712 ◽  
Author(s):  
Lin Fu ◽  
Jialei Qi ◽  
Xiang Gao ◽  
Ninghan Zhang ◽  
Huihui Zhang ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Poor Prognosis ◽  
High Expression ◽  
Acute Myeloid

scholarly journals DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications

Blood ◽  
2012 ◽  
Vol 119 (2) ◽  
pp. 559-568 ◽  
Author(s):  
Hsin-An Hou ◽  
Yuan-Yeh Kuo ◽  
Chieh-Yu Liu ◽  
Wen-Chien Chou ◽  
Ming Cheng Lee ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Poor Prognosis ◽  
De Novo ◽  
Clinical Course ◽  
Poor Prognostic Factor ◽  
Disease Evolution ◽  
Potential Biomarker ◽  
De Novo Aml ◽  
Acute Myeloid

Abstract DNMT3A mutations are associated with poor prognosis in acute myeloid leukemia (AML), but the stability of this mutation during the clinical course remains unclear. In the present study of 500 patients with de novo AML, DNMT3A mutations were identified in 14% of total patients and in 22.9% of AML patients with normal karyotype. DNMT3A mutations were positively associated with older age, higher WBC and platelet counts, intermediate-risk and normal cytogenetics, FLT3 internal tandem duplication, and NPM1, PTPN11, and IDH2 mutations, but were negatively associated with CEBPA mutations. Multivariate analysis demonstrated that the DNMT3A mutation was an independent poor prognostic factor for overall survival and relapse-free survival in total patients and also in normokaryotype group. A scoring system incorporating the DNMT3A mutation and 8 other prognostic factors, including age, WBC count, cytogenetics, and gene mutations, into survival analysis was very useful in stratifying AML patients into different prognostic groups (P < .001). Sequential study of 138 patients during the clinical course showed that DNMT3A mutations were stable during AML evolution. In conclusion, DNMT3A mutations are associated with distinct clinical and biologic features and poor prognosis in de novo AML patients. Furthermore, the DNMT3A mutation may be a potential biomarker for monitoring of minimal residual disease.

High expression of HOXA5 is associated with poor prognosis in acute myeloid leukemia

2020 ◽  
pp. 100673
Author(s):  
You Yang ◽  
Fangfang Zhong ◽  
Xiaoming Huang ◽  
Na Zhang ◽  
Jingjing Du ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Poor Prognosis ◽  
High Expression ◽  
Acute Myeloid

Overexpression of Apollon, an Antiapoptotic Protein, Is Associated with Poor Prognosis in Childhood De novo Acute Myeloid Leukemia

2007 ◽  
Vol 13 (17) ◽  
pp. 5109-5114 ◽  
Author(s):  
Ki Woong Sung ◽  
Jaewon Choi ◽  
Yu Kyeong Hwang ◽  
Sang Jin Lee ◽  
Hee-Jin Kim ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Poor Prognosis ◽  
De Novo ◽  
Antiapoptotic Protein ◽  
Acute Myeloid

scholarly journals High expression of dedicator of cytokinesis 1 (DOCK1) confers poor prognosis in acute myeloid leukemia

Oncotarget ◽  
2017 ◽  
Vol 8 (42) ◽  
pp. 72250-72259 ◽  
Author(s):  
Sze-Hwei Lee ◽  
Yu-Chiao Chiu ◽  
Yi-Hung Li ◽  
Chien-Chin Lin ◽  
Hsin-An Hou ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Poor Prognosis ◽  
High Expression ◽  
Acute Myeloid

scholarly journals Allogeneic Hematopoietic Stem Cell Transplantation Overcomes the Poor Prognosis in MLL-Rearranged Solid Tumor Therapy Related-Acute Myeloid Leukemia

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 39-40
Author(s):  
Hanzhou Qi ◽  
Hua Jin ◽  
Qifa Liu
Keyword(s):  
Acute Myeloid Leukemia ◽  
Solid Tumor ◽  
Myeloid Leukemia ◽  
Poor Prognosis ◽  
De Novo ◽  
Tumor Therapy ◽  
The Poor ◽  
De Novo Aml ◽  
Solid Tumor Therapy ◽  
Acute Myeloid

BACKGROUND: MLL rearrangement is very common in solid tumor therapy-related acute myeloid leukemia (t-AML). This study investigated the prognosis of MLL t-AML. METHODS: Patients with solid tumor t-AML and MLL de novo AML were enrolled in this retrospective study. The patients were divided into 3 groups: non-MLL t-AML(n=41), MLL t-AML(n=18) and MLL de novo AML(n=98). RESULTS: Of the 157 patients enrolled, 150 patients underwent anti-leukemia therapy. The complete remission (CR) rate was 83.3%, 85.5% and 86.2%(P=0.251), respectively, in MLL t-AML, non-MLL t-AML and MLL AML groups. The 3-years overall survival (OS) was 37.5%, 21.5% and 20.4% (P=0.046). The 3-years leukemia-free survival (LFS) was 28.0%, 32.2% and 22.7% (P=0.031), and the incidence of relapse was 30.0%, 50.4% and 53.5% (P=0.382), respectively, in the three groups. Multivariate analysis revealed that MLL t-AML was a risk factor while allo-HSCT a protective factor for relapse, LFS, and OS (P=0.005, P&lt;0.001 and P&lt;0.001) (P&lt;0.001, P&lt;0.001 and P=0.002, respectively). The 3-years OS was 0%, 17.9% and 0%(P=0.038), LFS was 0%, 23.1% and 0%(P=0.017), and relapse was 100%, 53.1% and 74.4% (P=0.001), respectively among three groups in patients undergoing chemotherapy alone, while OS was 64.3%, 52.7% and 40.7% (P=0.713), LFS was 60.0%, 48.8% and 37.0% (P=0.934), and relapse was 25.0%, 47.4% and 47.5% (P=0.872), respectively, among these group in the patients undergoing allo-HSCT. Intriguingly, MLL t-AML was no longer risk factor for relapse and LFS (P=0.882 and P=0.484, respectively), while it became a favorable factor for OS (P=0.011) in the patients undergoing allo-HSCT CONCLUSIONS: MLL t-AML had poor prognosis compared with non-MLL t-AML and MLL de novo AML,, but allo-HSCT might overcome the poor prognosis of MLL t-AML. Disclosures Liu: Nanfang Hospital, Southern Medical University: Research Funding.

scholarly journals Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia

Oncotarget ◽  
2016 ◽  
Vol 7 (8) ◽  
pp. 9084-9101 ◽  
Author(s):  
Hsin-An Hou ◽  
Chieh-Yu Liu ◽  
Yuan-Yeh Kuo ◽  
Wen-Chien Chou ◽  
Cheng-Hong Tsai ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Poor Prognosis ◽  
De Novo ◽  
Splicing Factor ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document